Revenio Group OyjREVXF 82 Return-on-Tangible-Equity is 33.80% as of Mar. 2026, which is 60% below its 10-year median of 83.50. GuruFocus rates REVXF with a GF Score™ of 82/100 and a GF Value™ of $40.83 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 92.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Revenio Group Oyj's annualized net income for the quarter that ended in Mar. 2026 was $11.6 Mil. Revenio Group Oyj's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $34.2 Mil. Therefore, Revenio Group Oyj's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 33.80%.
The historical rank and industry rank for Revenio Group Oyj's Return-on-Tangible-Equity or its related term are showing as below:
REVXF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 52.94 Med: 83.5 Max: 1122.55
Current: 61.04
During the past 13 years, Revenio Group Oyj's highest Return-on-Tangible-Equity was 1,122.55%. The lowest was 52.94%. And the median was 83.50%.
REVXF's Return-on-Tangible-Equity is ranked better than 92.5% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs REVXF: 61.04
Revenio Group Oyj (OTCPK:REVXF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Revenio Group Oyj Return-on-Tangible-Equity Related Terms
Revenio Group Oyj Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REVXF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Revenio Group Oyj's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 33.80% mean?
Revenio Group Oyj (REVXF) has a Return-on-Tangible-Equity of 33.80% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Revenio Group Oyj and its competitors. This is 60% below median its historical median of 83.50. Over the past decade, Revenio Group Oyj's Return-on-Tangible-Equity has ranged from 52.94 to 1,122.55. According to the industry distribution chart, Revenio Group Oyj ranks #57 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Revenio Group Oyj's Return-on-Tangible-Equity too high?
Revenio Group Oyj's current Return-on-Tangible-Equity of 33.80% is 60% below median its 10-year median of 83.50. Over the past 10 years, this metric has ranged from a low of 52.94 to a high of 1,122.55. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Revenio Group Oyj's value of 33.80% is 738.7% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #57 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #57 out of 760 companies for Return-on-Tangible-Equity. This places Revenio Group Oyj in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Revenio Group Oyj's value of 33.80% is 738.7% above this benchmark. Historically, Revenio Group Oyj's own Return-on-Tangible-Equity has ranged from 52.94 to 1,122.55 over the past decade. While the company's 10-year median is 83.50 vs. the industry median of 4.03, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Return-on-Tangible-Equity of 33.80% is 738.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Return-on-Tangible-Equity is 33.80%, which is 60% below median its own 10-year median of 83.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.83, compared to a current price of $16.41 — trading 59.8% below its estimated fair value. The current Return-on-Tangible-Equity is 33.80%, which is 60% below median its 10-year median of 83.50 and 738.7% above the Medical Devices & Instruments industry median of 4.03. Revenio Group Oyj's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current Return-on-Tangible-Equity is 33.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 59.8% below its estimated GF Value™ of $40.83.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
Return-on-Tangible-Equity: 33.80% (60% below median its 10-year median of 83.50)
GF Value™: $40.83 vs. price of $16.41 (59.8% below fair value)
Industry Position: 738.7% above the Medical Devices & Instruments median (#57 of 760)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score
Get the complete analysis for REVXF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
